Low Blood Pressure (Antihypertensive Therapy) is Most Likely Responsible
Among the medications listed, low blood pressure from antihypertensive therapy is the most likely cause of urinary frequency, polyuria, and dizziness in this patient. This triad of symptoms is classic for symptomatic hypotension and volume depletion, particularly in patients on blood pressure medications.
Clinical Reasoning
Primary Culprit: Antihypertensive Medications
Dizziness is a hallmark symptom of hypotension and is directly addressed in multiple guidelines as a common adverse effect of blood pressure medications 1, 2, 3. The JNC-7 guidelines specifically identify orthostatic hypotension as causing "postural unsteadiness, dizziness, or even fainting" 1. Recent evidence confirms that dizziness is one of the most frequently reported blood pressure medication side effects, with 90% of patients on antihypertensives reporting at least one symptom 3.
The combination of polyuria and urinary frequency strongly suggests diuretic therapy, which is commonly used as part of antihypertensive regimens. Diuretics directly cause increased urination by design, and when combined with other blood pressure medications, can lead to volume depletion and symptomatic hypotension 2.
The 2025 Heart Failure Association guidelines note that "diuretics will need to be adjusted according to volume status and may result in lower BP with overdiuresis" 2. This creates a vicious cycle where excessive diuresis leads to both urinary symptoms AND hypotension-related dizziness.
Why Not the Other Medications?
Crestor (Rosuvastatin): While rosuvastatin can cause renal effects, the FDA label does not list dizziness, polyuria, or urinary frequency as common adverse effects 4. The primary renal concerns with rosuvastatin are hematuria and proteinuria (detected on urinalysis, not symptomatic frequency) 5. Rosuvastatin does not cause hypotension or volume-related symptoms.
Eliquis (Apixaban): The FDA label for apixaban focuses on bleeding risks and does not list urinary frequency, polyuria, or dizziness as adverse effects 6. Anticoagulants do not affect blood pressure or urinary patterns unless bleeding complications occur (which would present differently).
Fenofibrate: While fenofibrate can cause modest increases in serum creatinine 7, 8, it does not typically cause symptomatic urinary frequency or polyuria. The 2013 ACC/AHA cholesterol guidelines note that fenofibrate-simvastatin "was more likely to increase creatinine level" but this represents a laboratory finding, not symptomatic polyuria 7. Fenofibrate does not cause hypotension or dizziness as primary effects.
Clinical Approach
Immediate Assessment Steps
Measure orthostatic vital signs: Check blood pressure and heart rate supine and after standing for 1-3 minutes. Orthostatic hypotension is defined as a drop of ≥20 mmHg systolic or ≥10 mmHg diastolic 1.
Review current blood pressure readings: If systolic BP is <120 mmHg or the patient has symptoms with BP <130 mmHg, antihypertensive adjustment is needed 9, 2.
Assess volume status: Look for signs of overdiuresis including dry mucous membranes, decreased skin turgor, and postural symptoms.
Identify the specific antihypertensive regimen: Determine if diuretics are being used and at what dose. Assess for polypharmacy (≥5 medications), which significantly increases risk of hypotension-related adverse events 10, 3.
Management Strategy
If symptomatic hypotension is confirmed:
- Reduce or discontinue diuretics first if volume depletion is present 2
- Consider reducing doses of other antihypertensives, particularly if BP is <130/80 mmHg
- The 2025 HFA guidelines emphasize that "symptomatic hypotension in chronic [patients], typically characterized by mild dizziness upon standing, can usually be managed through patient education and counselling" 2, but medication adjustment is warranted when symptoms are bothersome
Do not adjust statin or anticoagulant therapy for these symptoms, as they are not the cause.
Important Caveats
Age and Polypharmacy Considerations
Older patients (≥70 years) are at significantly higher risk for hypotension-related adverse events (OR 1.29) 10. Patients taking 5-9 medications have OR 1.27 for adverse events, while those on ≥10 medications have OR 2.37 10. This patient likely falls into these high-risk categories.
Blood Pressure Targets
The 2020 ISH guidelines recommend BP targets <130/80 mmHg in most patients, but <140/80 mmHg in elderly patients 9. Overly aggressive BP lowering can cause more harm than benefit through symptomatic hypotension.
Monitoring After Adjustment
After reducing antihypertensive therapy, monitor BP closely to ensure it remains controlled. The goal is to eliminate symptoms while maintaining adequate BP control for cardiovascular protection.